EDAP TMS (EDAP) & Boston Scientific Corporation (BSX) Financial Contrast

EDAP TMS (NASDAQ: EDAP) and Boston Scientific Corporation (NYSE:BSX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Institutional and Insider Ownership

9.4% of EDAP TMS shares are owned by institutional investors. Comparatively, 90.3% of Boston Scientific Corporation shares are owned by institutional investors. 0.7% of Boston Scientific Corporation shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for EDAP TMS and Boston Scientific Corporation, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EDAP TMS 0 0 1 0 3.00
Boston Scientific Corporation 0 4 12 0 2.75

EDAP TMS presently has a consensus target price of $6.50, suggesting a potential upside of 105.70%. Boston Scientific Corporation has a consensus target price of $30.58, suggesting a potential upside of 4.00%. Given EDAP TMS’s stronger consensus rating and higher possible upside, analysts clearly believe EDAP TMS is more favorable than Boston Scientific Corporation.

Profitability

This table compares EDAP TMS and Boston Scientific Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
EDAP TMS -0.27% 10.31% 5.56%
Boston Scientific Corporation 9.04% 23.62% 9.01%

Earnings & Valuation

This table compares EDAP TMS and Boston Scientific Corporation’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
EDAP TMS $44.00 million 2.08 $270,377.00 ($0.01) -315.68
Boston Scientific Corporation $8.71 billion 4.63 $2.31 billion $0.58 50.69

Boston Scientific Corporation has higher revenue and earnings than EDAP TMS. EDAP TMS is trading at a lower price-to-earnings ratio than Boston Scientific Corporation, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

EDAP TMS has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, Boston Scientific Corporation has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Summary

Boston Scientific Corporation beats EDAP TMS on 11 of the 14 factors compared between the two stocks.

About EDAP TMS

EDAP TMS S.A. (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors. The Company also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) and distributes other types of urology devices in certain countries. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the invasive treatment of urological and other clinical indications. The UDS division is engaged in the development, marketing, manufacturing and servicing of medical devices for the invasive diagnosis or treatment of urological disorders, urinary stones, and other clinical indications.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Receive News & Ratings for EDAP TMS S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EDAP TMS S.A. and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.